Reduction in the Prices of Drugs

2037. SHRIMATI PRATIBHA SINGH: Will the Minister of PETROLEUM AND CHEMICALS be pleased to state:

(a) whether it is a fact that his Ministry based on notification dated 20th March, 1990 called details from Drug industry to revise the prices of bulk drugs consequent to reduction in customs duty on the intermediates going into the production of those drugs;

(b) whether it is also a fact that his Ministry gave time limit upto 10th May, 1990 for providing the details;

(c) if so, what are the names of the companies which provided the information called for;

(d) what are the names of bulk drugs for which reduced customs duty intermediates are used;

(e) what was the rate of customs duty on each intermediate before and after reduction;

(f) what are the names of bulk drugs for which prices have been reduced after suitable adjustment; and

(g) by when the prices of remaining drugs would be reduced to give relief to people?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M.S. GURUPADASWAMY): (a) and (b) Details for reduction in prices of bulk drugs consequent to reduction in customs duty on 41 intermediates with effect from 20th March, 1990, were called from the-manufacturers, Industry Associations and the BICP.

(c), (f) and (g) Exercises for adjusting the prices of the bulk drugs consequent to reduction in Customs Duty are already in progress based on the information received from the various sources.

(d) and (e) Customs duty on connected intermediates which would have been normally leviable at 148.86% *ad valorem* have been reduced to 115% *ad valorem*. The names of bulk drugs affected by said duty reduction are given in the annexed statement.

Statement

1. Alprazolen
2. Astemizole
3. Azetheprime
4. Beclomethasone
5. Betamethasone
6. Captopril
7. Carbamazepine
8. Cefadroxyl
9. Cofadroxyl Monohydrate
10. Cephazelin Sodium
11. Chloramphenicol
12. Ciprofloxalin
13. Clopamide
14. Clotrimazole
15. Danazole.
16. Desogestrel
17. Diclofenac Sodium
18. Dimenhydrinate
19. Doxycycline and its salts
20. Furazolidone
21. Guaiacol Glyceryl ether
22. Hydrocortisone
23. Ketamine Hcl
24. Loperamide
25. Methocarbamel
26. Miconazole
27. Pentoxyfylline
28. Promethazine Theoclate
29. Sulbactem Sodium Ester/Pivalol.
30. Terbutaline sulphate
31. Testostrome Esters
32. Triamcinolone
33. Trimethoprim.

Submission of details regarding drugs in Form 6

2038. SHRI ASHOK NATH VERMA: Will the Minister of PETROLEUM AND CHEMICALS be pleased to state:

(a) whether it is a fact that a number of drug companies are importing drug intermediates and raw materials under OGL for the production of drugs for which they are not eligible as per the

conditions of manufacturing permission granted under ID & R Act;

(b) whether it is also a fact that certain drug companies which have been permitted to produce formulations based on their own produced bulk drugs are importing those drugs under OGL;

(c) whether it is also a fact that every producer of bulk drug and formulator has to provide such information in Form 6 as per provision 22 of DPCO, 1987;

(d) if so, what are the names of the companies which submitted Form 6 during 1988 and 1989; and

(e) what are the details of Form 6 scrutinised by his Ministry and what is the reaction on each?

THE MINISTER FOR PETROLEUM AND CHEMICALS (SHRI M.S. GURUPADASWAMY): (a) Import of drug intermediates and raw materials is not monitored by this Ministry. However, import for indigenous production is regulated by the stage of manufacture indicated in the industrial licence or registration.

(b) This Ministry has not received any reports in this connection.

(c) Yes, Sir.

(d) Details are given in the statement (See below).

(c) Scrutiny of the details relating to the profitability on the formulation activity showed that the concerned 17 companies are well within the ceilings provided in DPCO, 1987.

Statement

Sl.No.	Name of the Company
1	M/s. Win-Medicare Ltd.
2	M/s. J.L. Morison (I) Ltd.
3	M/s. Raptakos, Bratt & Co. Ltd.
4	M/s. Glindia Ltd.
5	M/s. Liva Pharma Pvt. Ltd.
6	M/s. Iodon Labs. Pvt. Ltd.
7	M/s. May & Baker (I) Ltd.
8	M/s. Hindustan Ciba-Geigy Ltd.
9.	M/s. Marind Ltd.
10.	M/s. Unique Pharmaceutical Labs. Ltd.
11.	M/s. John Wyeth (I) Ltd.
12.	M/s. Hoechst India Ltd.
13.	M/s. Cevee Pharma Pvt. Ltd.
14.	M/s. Burroughs Wellcome
15.	M/s. Duphar Interfran Ltd.
16.	M/s. Wyeth Labs.
17.	M/s. Ifunik Pharma.

Overcharging of Analgin

2039. SHRI BEKAL UTSAHI: Will the Minister of PETROLEUM AND CHEMICALS be pleased to refer to the answer to Unstarred Question 826 given in the Rajya Sabha on the 19th March, 1990 and state:

(a) whether it is a fact that Government can obtain the details by exercising the powers available under DPCO, 1979/1987 relating to procurement of Analgin by the formulators of Novalgin;

(b) if so, what steps are being taken to obtain the details of procurement during the last three years, year-wise;

(c) whether it is also a fact that while fixing the prices of formulations the rate of Analgin taken into consideration was Rs. 338/- and not Rs. 313/- per kg.;

(d) whether it is also a fact that the company procured Analgin at Rs. 260/- per kg.; and thus overcharged the consumer by Rs. 78/- per kg.;

(e) whether it is also a fact that the overcharged amount comes to Rs. 4 crores per annum; and

(f) if so, what are the details in this regard and what action has been taken against the company?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M.S. GURUPADASWAMY): (a) Yes, Sir.

(b), (d) to (f) The necessary details are being collected from the company